Corsair Gaming Inc vs Heron Therapeutics Inc — how do they compare? Corsair Gaming Inc trades at $13.64 (market cap $1.42B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Corsair Gaming Inc is far larger — about 20.9× Heron Therapeutics Inc's market cap, and Corsair Gaming Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Heron Therapeutics Inc for 35 Days on average.
| CRSR | HRTX | |
|---|---|---|
Market Cap | $1.42B | $68.01M |
Volume | 1,160,938 | 1,891,941 |
Sector | Technology | Health |
52-Week High | $14.35 | $1.49 |
52-Week Low | $4.58 | $0.27 |
Typical Hold Time | 25 Days | 35 Days |
Enterprise Value | $1.41B | $174.75M |
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $13.63, up 0.29% with a bullish technical signal. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.23 exceeding expectations by 228%. Recent product launches like the VOXARA microphone and strategic acquisitions demonstrate growth initiatives. Financials show improving cash flow trends with projected 2026 operating cash flow of $106 million, though net income margins remain thin at 2.53%.
CRSR presents a mixed outlook with strong earnings momentum and product innovation offset by valuation concerns at 42x P/E. Analyst consensus is cautious with 64% hold ratings and $12.40 price target below current levels. Key risks include competitive gaming peripherals market and execution of growth strategy. The stock's near-term direction hinges on Q3 earnings delivery and sustained margin improvement.
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →